NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis → Next President (Not Trump. Not Biden.) (From The Freeport Society) (Ad) Free CNSP Stock Alerts $0.20 0.00 (0.00%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$0.20▼$0.2250-Day Range$0.19▼$0.3852-Week Range$0.19▼$2.98Volume536,399 shsAverage Volume407,662 shsMarket Capitalization$2.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get CNS Pharmaceuticals alerts: Email Address Ad The Freeport SocietyNext President (Not Trump. Not Biden.)Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be Trump.Click here to see why it will be ______ _________. About CNS Pharmaceuticals Stock (NASDAQ:CNSP)CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Read More CNSP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNSP Stock News HeadlinesMay 22, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company ShowcaseMay 16, 2024 | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024May 16, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2024 Financial ResultsApril 25, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024April 4, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate UpdateApril 3, 2024 | benzinga.comCNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and RevenueApril 2, 2024 | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023March 20, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to BoardFebruary 9, 2024 | investing.comCns Pharmaceuticals Inc (CNSP)February 3, 2024 | msn.comCNS Pharmaceuticals Launches Public Offering for Trial FundingJanuary 30, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering PricingJanuary 29, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 29, 2024 | finance.yahoo.comCNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 19, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of DirectorsJanuary 18, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 18, 2024 | finance.yahoo.comBiotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 17, 2024 | finance.yahoo.comCNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)January 6, 2024 | seekingalpha.comCNSP CNS Pharmaceuticals, Inc.December 18, 2023 | finance.yahoo.comCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of BerubicinDecember 14, 2023 | morningstar.comCNS Pharmaceuticals Inc Ordinary SharesDecember 8, 2023 | msn.comCNS Pharmaceuticals files to sell 3.81M shares of common stockDecember 6, 2023 | finance.yahoo.comHow CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No CureNovember 22, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of EfficacyNovember 21, 2023 | msn.comCNS Pharmaceuticals files to sell 3.76M shares of common stock for holdersNovember 16, 2023 | finance.yahoo.comCNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug CandidateSee More Headlines Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today5/28/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNSP CUSIPN/A CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.48) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-603.40% Return on Assets-575.33% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.71) per share Price / Book-0.29Miscellaneous Outstanding Shares11,850,000Free Float10,762,000Market Cap$2.43 million OptionableNot Optionable Beta2.78 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. John Michael Climaco Esq. (Age 55)J.D., CEO, President & Director Comp: $525kMr. Christopher S. Downs CPA (Age 45)CTP, FP&A, Chief Financial Officer Comp: $382.16kDr. Sandra L. Silberman M.D. (Age 68)Ph.D., Chief Medical Officer Comp: $261.2kDr. Waldemar Priebe Ph.D.FounderDr. Donald H. Picker Ph.D. (Age 78)Chief Science Officer Key CompetitorsAdamis PharmaceuticalsNASDAQ:ADMPNuCanaNASDAQ:NCNAOragenicsNYSE:OGENAlterity TherapeuticsNASDAQ:ATHEAddex TherapeuticsNASDAQ:ADXNView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 81,094 shares on 5/20/2024Ownership: 0.795%Christopher DownsBought 27,000 shares on 8/22/2023Total: $34,290.00 ($1.27/share)John M ClimacoBought 2,750 shares on 8/16/2023Total: $4,950.00 ($1.80/share)View All Insider TransactionsView All Institutional Transactions CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed in 2024? CNS Pharmaceuticals' stock was trading at $1.27 at the start of the year. Since then, CNSP shares have decreased by 83.9% and is now trading at $0.2049. View the best growth stocks for 2024 here. Are investors shorting CNS Pharmaceuticals? CNS Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 62,500 shares, an increase of 100.3% from the April 30th total of 31,200 shares. Based on an average trading volume of 354,100 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.6% of the shares of the company are sold short. View CNS Pharmaceuticals' Short Interest. When is CNS Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CNSP earnings forecast. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) posted its earnings results on Monday, April, 1st. The company reported ($0.95) EPS for the quarter. When did CNS Pharmaceuticals' stock split? CNS Pharmaceuticals's stock reverse split on the morning of Tuesday, November 29th 2022. The 1-30 reverse split was announced on Tuesday, November 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, November 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Block (SQ). When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $9 million in an IPO on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO. Who are CNS Pharmaceuticals' major shareholders? CNS Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.80%). Insiders that own company stock include Christopher Downs, Jerzy Gumulka, John M Climaco and Waldemar Priebe. View institutional ownership trends. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNSP) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
